文献速递乳腺癌

EORTC 22922/10925 试验 pN0 乳腺癌 20 年亚组分析:内乳及内侧锁骨上淋巴结照射

Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.
PubMed 文献 · Lancet Oncol · 2026-01-01

该研究为随机对照三期试验的非计划亚组分析,纳入 888 例 IM-MS 照射组和 890 例对照组 pN0 乳腺癌患者。

核心结论

  • pN0 乳腺癌患者中,IM-MS 照射 20 年乳腺癌死亡率显著降低,但非乳腺癌死亡率数值更高,总生存无长期获益。

研究设计与样本

  • EORTC 22922/10925 为随机、开放标签、三期试验,在 13 个国家 46 个放疗科开展。
  • 本分析为非计划 pN0 亚组分析,纳入 888 例 IM-MS 照射组和 890 例对照组患者。
  • IM-MS 照射剂量为 50 Gy/25 次,主要终点为总生存,按意向性治疗分析。

临床怎么用

  • 对 pN0 且肿瘤位于中央或内侧的乳腺癌患者,IM-MS 照射可降低乳腺癌死亡率,但需权衡非乳腺癌死亡风险。
  • 应使用先进放疗技术降低心脏和肺等危及器官剂量,并重视长期随访。

局限性

  • 本分析为未计划的亚组分析,pN0 患者仅占全部随机人群的一部分。
  • 开放标签设计,患者和研究者在分配时未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Results from several studies, including our 15-year analysis, showed improved disease-free survival and distant metastasis-free survival, reduced breast cancer-related mortality, and variable effects on overall survival with the addition of partial or comprehensive regional lymph node irradiation after surgery in patients with breast cancer. Here, we present the scheduled 20-year analysis of the EORTC trial 22922/10925, evaluating the role of internal mammary and medial-supraclavicular (IM-MS) nodal irradiation in patients with stage I-III breast cancer. Patients without confirmed axillary nodal involvement (pathological N stage 0 [pN0]) were eligible for the trial when the primary tumours were centrally or medially located. METHODS: EORTC 22922/10925 was a randomised, open-label, phase 3 trial done across 46 radiation oncology departments from 13 countries. Eligible participants were women up to 75 years of age with unilateral, histologically confirmed, stage I-III breast adenocarcinoma with involved axillary nodes or a central or medially located primary tumour. Patients were randomly assigned (1:1) centrally using minimisation to receive IM-MS irradiation at 50 Gy in 25 fractions (IM-MS irradiation group) or no IM-MS irradiation (control group). Stratification was done for institution, menopausal status, site of the primary tumour within the breast, type of breast and axillary surgery, and pathological T and N stage. Patients and investigators were not masked to treatment allocation. Only patients without clinically and histopathologically confirmed nodal involvement (pN0) were included in this unplanned subgroup analysis. The primary outcome was overall survival analysed according to the intention-to-treat principle. Safety analyses were conducted in the subset of eligible patients treated per protocol. This trial is registered with ClinicalTrials.gov (on Nov 1, 1999; NCT00002851) and closed after its final analysis. FINDINGS: Between Aug 5, 1996, and Jan 13, 2004, 4004 patients were randomly assigned. 890 (44·5%) of 2002 patients in the IM-MS irradiation group and 888 (44·4%) of 2002 patients in the control group had pN0 disease. The median age of participants was 55 years (IQR 48-63). At a median follow-up of 22·2 years (IQR 20·1-24·5), 276 (31·1%) of 888 patients in the IM-MS irradiation group and 277 (31·1%) of 890 patients in the control group died because of any cause; 87 (31·5%) of 276 and 122 (44·0%) of 277 patients died due to breast cancer, respectively. At 20 years, the overall survival rate was 69·0% (95% CI 65·4-72·3) in the IM-MS irradiation group and 68·4% (64·8-71·6%) in the control group (hazard ratio [HR] 0·98 [95% CI 0·83-1·15], p=0·77). The breast cancer mortality rate was 10·0% (8·0-12·3) in the IM-MS irradiation group and 14·2% (11·9-16·8) in the control group (HR 0·70 [95% CI 0·53-0·92], p=0·010), but cumulative mortality of unknown cause or not breast cancer cause was 20·9% (95% CI 17·9-24·1) in the IM-MS irradiation group and 17·4% (14·7-20·3) in the control group (HR 1·24 [95% CI 1·00-1·53]; p=0·048). In patients with left-sided breast cancer, late cardiac fibrosis occurred in 15 (3·4%) of 445 patients in the IM-MS irradiation group and 12 (2·8%) of 436 patients in the control group. Lung fibrosis at any grade occurred in 55 (6·4%) of 855 patients in the IM-MS irradiation group and 18 (2·1%) of 877 patients in the control group. INTERPRETATION: Breast cancer mortality at 20 years was significantly lower in the IM-MS irradiation group, whereas non-breast cancer mortality was numerically higher in the IM-MS irradiation group after 15 years, resulting in no long-term benefit of IM-MS irradiation on overall survival. Our results emphasise the importance of very long-term follow-up and advanced irradiation techniques to reduce the dose to organs of interest. FUNDING: Ligue Nationale contre le Cancer, KWF Kankerbestrijding, and EORTC Cancer Research Fund.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kaidar-Person O, Weltens CG, Fortpied C, et al. Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer. Lancet Oncol. 2026. PMID: 42372743. doi:10.1016/S1470-2045(26)00233-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。